Role of the eNOS-NO System in Regulating the Antiproteinuric Effects of VEGF Receptor 2 Inhibition in Diabetes
Figure 1
Systolic blood pressure (SBP) and proteinuria in nondiabetic Ren-2 rats treated with vehicle or vandetanib for 14 days and then observed for further 10 days. The graphs illustrate that the development of proteinuria with vandetanib precedes the rise in SBP.
